Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNMD Mind Medicine (MindMed) Inc.

Market Closed 05-03 16:00:00 EDT

10.00

+0.48

+5.04%

盘后10.06

+0.06+0.60%

19:58 EDT

High10.34	Low9.64	Vol1.09M
Open9.67	D1 Closing9.52	Amplitude7.35%
Mkt Cap718.72M	Tradable Cap578.41M	Total Shares71.87M
T/O10.92M	T/O Rate1.88%	Tradable Shares57.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MNMD","market":"US","secType":"STK","nameCN":"Mind Medicine (MindMed) Inc.","latestPrice":10,"timestamp":1714766400000,"preClose":9.52,"halted":0,"volume":1087720,"hourTrading":{"tag":"盘后","latestPrice":10.06,"preClose":10,"latestTime":"19:58 EDT","volume":8381,"amount":83733.246,"timestamp":1714780734887},"delay":0,"floatShares":57840618,"shares":71872422,"eps":-2.444798,"marketStatus":"Market Closed","change":0.48,"latestTime":"05-03 16:00:00 EDT","open":9.67,"high":10.34,"low":9.64,"amount":10916857.18348,"amplitude":0.073529,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.444798,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1714982400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":9.52,"preHourTrading":{"tag":"盘前","latestPrice":9.69,"preClose":9.52,"latestTime":"09:27 EDT","volume":3763,"amount":36988.081119,"timestamp":1714742870125},"postHourTrading":{"tag":"盘后","latestPrice":10.06,"preClose":10,"latestTime":"19:58 EDT","volume":8381,"amount":83733.246,"timestamp":1714780734887},"volumeRatio":1.099928,"optionData":{"bulkOrders":[{"symbol":"MNMD","call":true,"expireDate":1715918400000,"strike":"10.0","timestamp":1714762484888,"price":0.85,"volume":3694,"amount":313990,"type":"+"},{"symbol":"MNMD","call":false,"expireDate":1715918400000,"strike":"9.0","timestamp":1714762484888,"price":0.35,"volume":3607,"amount":126245,"type":"+"}]}},"requestUrl":"/m/hq/s/MNMD","defaultTab":"news","newsList":[{"id":"2432676471","title":"Press Release: MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2432676471","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432676471?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:14","pubTimestamp":1714648440,"startTime":"0","endTime":"0","summary":"MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update. Mind Medicine  Inc.  , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the first quarter ended March 31, 2024.MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2431081171","title":"Psychedelic drug developers could benefit from NIH funding for chronic pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2431081171","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431081171?lang=en_us&edition=fundamental","pubTime":"2024-04-30 01:37","pubTimestamp":1714412227,"startTime":"0","endTime":"0","summary":"The National Institutes of Health recently announced it is offering $8.4M to support trials examining the efficacy and safety of psychedelic treatments for chronic pain. The notice, posted April 24, said that the research can include psilocybin , LSD, mescaline, and MDMA, also known as ecstasy.  \"A potential novel approach to treatment of chronic pain in adults involves psychedelic-assisted therapy ,\" the notice states. \"Evidence for the efficacy of PAT has been particularly notable in depression, anxiety , post-traumatic stress disorder , and substance use disorders, among other indications.\"  Marijuana Moment first reported the development on Monday. Several companies involved in developing psychedelic-based therapies could potentially benefit from the funding. These include Mind Medicine , Atai Life Sciences , Cybin , COMPASS Pathways , Lucy Scientific Discovery , 180 Life Sciences , Bright Binds Bioscience , and Seelos Theraspeutics .","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157676497/image_157676497.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157676497/image_157676497.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095746-psychedelic-drug-developers-could-benefit--nih-funding-chronic-pain","is_publish_highlight":false,"gpt_icon":0},{"id":"2430181223","title":"MindMed: Breakthrough Status From The FDA For LSD Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2430181223","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430181223?lang=en_us&edition=fundamental","pubTime":"2024-04-26 17:33","pubTimestamp":1714124023,"startTime":"0","endTime":"0","summary":"MindMed's LSD tartrate receives breakthrough therapy designation from the FDA for the treatment of generalized anxiety disorder.GAD affects a significant portion of the US population, with high costs ","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157611061/image_157611061.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157611061/image_157611061.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4686589-mindmed-breakthrough-status-from-the-fda-for-lsd","is_publish_highlight":false,"gpt_icon":0},{"id":"2430253467","title":"The Top 3 Small-Cap Stocks to Buy in April 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2430253467","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2430253467?lang=en_us&edition=fundamental","pubTime":"2024-04-26 03:00","pubTimestamp":1714071600,"startTime":"0","endTime":"0","summary":"These top small-cap stocks offer investors diversification across multiple segments but boast a strong standing on their own merits.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/04/the-top-3-small-cap-stocks-to-buy-in-april-2024/","is_publish_highlight":false,"gpt_icon":0},{"id":"2430409079","title":"MindMed to Present at Upcoming May Medical Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2430409079","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2430409079?lang=en_us&edition=fundamental","pubTime":"2024-04-25 19:00","pubTimestamp":1714042800,"startTime":"0","endTime":"0","summary":"NEW YORK, April 25, 2024----Mind Medicine  Inc. , , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder , as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:. American Psychiatric Association  2024 Congress, New York, NYTitle: Rapid and Durable Response to a Single Dose of MM120  in Generalized Anxiety Disorder: A Dose-Optimization StudyFormat: PosterPresenter: Dan Karlin, MDDate: Saturday, May 4, 2024. Title: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety DisorderFormat: PosterPresenter: Phong Duong, PharmDDate: Saturday, May 4, 2024. Certain statements in this news release related to the Company constitute \"forward-looking information\" within the meaning of applicable securities laws and","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/O74dO22ow3_3qUq0BEix_w--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/01847d73379adfa3faf512ce3e9854c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/O74dO22ow3_3qUq0BEix_w--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/01847d73379adfa3faf512ce3e9854c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-present-upcoming-may-medical-110000793.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425994299","title":"MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2425994299","media":"Nasdaq","top":-1,"share":"https://ttm.financial/m/news/2425994299?lang=en_us&edition=fundamental","pubTime":"2024-04-08 20:32","pubTimestamp":1712579552,"startTime":"0","endTime":"0","summary":"MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMiU2h0dHBzOi8vd3d3Lm5hc2RhcS5jb20vYXJ0aWNsZXMvbWluZG1lZC1tbm1kLXN0b2NrLXJpc2VzLTE1NC1pbi0zLW1vbnRoczotaGVyZXMtd2h50gEA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMiU2h0dHBzOi8vd3d3Lm5hc2RhcS5jb20vYXJ0aWNsZXMvbWluZG1lZC1tbm1kLXN0b2NrLXJpc2VzLTE1NC1pbi0zLW1vbnRoczotaGVyZXMtd2h50gEA?oc=5","is_publish_highlight":false,"gpt_icon":0},{"id":"2425317186","title":"Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2425317186","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2425317186?lang=en_us&edition=fundamental","pubTime":"2024-04-05 00:43","pubTimestamp":1712249011,"startTime":"0","endTime":"0","summary":"I believe there is, because of the positive data reported for starters. Also, because the FDA granted MM-120 Breakthrough Therapy Designation [BTD], which means that MM-120 could ultimately be granted Priority Review by the FDA for submission. In addition, this biotech is not pinning its hopes on only this one clinical product. That's because it is also advancing another candidate, known as MM-402, which is an R-MDMA. In essence, an improved MDMA being explored in a phase 1 IIT UHB sponsored study for the treatment of patients with autism spectrum disorder [ASD]. Topline data from this early-stage study is expected in the 1st half of 2024. Lastly, there is another data readout to consider, which would be the use of LSD to treat patients with psychiatric disorders like major depressive disorder [MDD], cluster headaches and anxiety. MM-120 Achieves Necessary Outcome For Late-Stage Clinical Study Advancement As I noted above, Mind Medicine was able to report positive results from its phas","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1938555135/image_1938555135.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1938555135/image_1938555135.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4682186-mind-medicine-gad-program-success-continues-btd-positive-treatment-data","is_publish_highlight":false,"gpt_icon":0},{"id":"2424201841","title":"MindMed to Present at Upcoming April Medical Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2424201841","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2424201841?lang=en_us&edition=fundamental","pubTime":"2024-04-02 19:00","pubTimestamp":1712055600,"startTime":"0","endTime":"0","summary":"NEW YORK, April 02, 2024----Mind Medicine  Inc. , , , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:. European Psychiatric Association  2024 CongressTitle: Prevalence of Generalized Anxiety Disorder Among Five European Countries Before and During COVIDFormat: PosterPresenter: Phong Duong, PharmDDate and Time: Tuesday, April 9, 2024, at 9:30 AMLocation: Budapest, Hungary. Posters will be available on MindMed’s Company website following the conferences.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3oynAVIFPTubsP94GsbF1g--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/95f893ae1f6a6d89d48d4e3c2408cd92","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3oynAVIFPTubsP94GsbF1g--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/95f893ae1f6a6d89d48d4e3c2408cd92"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-present-upcoming-april-medical-110000027.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424701479","title":"Mind Medicine Inc. Statement Inaccessible","url":"https://stock-news.laohu8.com/highlight/detail?id=2424701479","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2424701479?lang=en_us&edition=fundamental","pubTime":"2024-04-02 07:37","pubTimestamp":1712014644,"startTime":"0","endTime":"0","summary":"Mind Medicine Inc. (MNMD) has released an update. Mind Medicine Inc. has released a new statement with significant updates that could interest inve...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mind-medicine-inc-statement-inaccessible?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mind-medicine-inc-statement-inaccessible?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2424379703","title":"BRIEF-Mindmed Announces Voluntary Delisting From Cboe Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2424379703","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2424379703?lang=en_us&edition=fundamental","pubTime":"2024-04-02 06:23","pubTimestamp":1712010216,"startTime":"0","endTime":"0","summary":"April 1  - Mind Medicine  Inc :   * MINDMED ANNOUNCES VOLUNTARY DELISTING FROM CBOE CANADA   * MIND MEDICINE  INC: ALL COMMON SHARES WILL REMAIN LISTED ON NASDAQ   * MIND MEDICINE  INC: ELECTED TO VOLUNTARILY DELIST ITS COMMON SHARES FROM CBOE CANADA, EFFECTIVE AT CLOSE OF MARKETS ON APRIL 10Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424740557","title":"MindMed to voluntarily delist from CBOE Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2424740557","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424740557?lang=en_us&edition=fundamental","pubTime":"2024-04-02 05:10","pubTimestamp":1712005803,"startTime":"0","endTime":"0","summary":"Mind Medicine   has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed’s common shares will continue to be listed and tradable on The Nasdaq Global Select Market under the symbol “MNMD” and Canadian shareholders can continue to trade their shares on Nasdaq. The Company believes that the trading volume of its common shares on Cboe Canada no longer justifies the expense and administrative requirements associated with maintaining this dual listing. Source: Press Release    More on Mind Medicine  Mind Medicine  Inc.  Q4 2023 Earnings Call Transcript Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation Mind Medicine prices underwritten offering of shares and concurrent private placement","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4086032-mindmed-to-voluntarily-delist-from-cboe-canada","is_publish_highlight":false,"gpt_icon":0},{"id":"2424177407","title":"MindMed Announces Voluntary Delisting from Cboe Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2424177407","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2424177407?lang=en_us&edition=fundamental","pubTime":"2024-04-02 05:00","pubTimestamp":1712005200,"startTime":"0","endTime":"0","summary":"NEW YORK, April 01, 2024----Mind Medicine  Inc.   , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed’s common shares will continue to be listed and tradable on The Nasdaq Global Select Market  under the symbol \"MNMD\" and Canadian shareholders can continue to trade their shares on Nasdaq.MindMed trades on Nasdaq under the symbol MNMD and currently trades","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GbSWs4GW.OFDVOw80K95Rw--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2fb3f60dba4bf9678b01d14cc28affdf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GbSWs4GW.OFDVOw80K95Rw--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2fb3f60dba4bf9678b01d14cc28affdf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-announces-voluntary-delisting-cboe-210000971.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422687957","title":"Mind Medicine (NASDAQ:MNMD) is Leading the Surge in Psychedelic Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2422687957","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2422687957?lang=en_us&edition=fundamental","pubTime":"2024-03-27 16:49","pubTimestamp":1711529395,"startTime":"0","endTime":"0","summary":"There has been a massive surge in interest in psychedelic-assisted therapies, and Mind Medicine (NASDAQ:MNMD) is leading the companies poised to be...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/mind-medicine-nasdaqmnmd-is-leading-the-surge-in-psychedelic-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/mind-medicine-nasdaqmnmd-is-leading-the-surge-in-psychedelic-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2422952432","title":"Citigroup Inc. Purchases New Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422952432","media":"Defense World","top":-1,"share":"https://ttm.financial/m/news/2422952432?lang=en_us&edition=fundamental","pubTime":"2024-03-27 16:47","pubTimestamp":1711529256,"startTime":"0","endTime":"0","summary":"Citigroup Inc. Purchases New Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMieWh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8yNy9jaXRpZ3JvdXAtaW5jLXB1cmNoYXNlcy1uZXctcG9zaXRpb24taW4tbWluZC1tZWRpY2luZS1taW5kbWVkLWluYy1uYXNkYXFtbm1kLmh0bWzSAQA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMieWh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8yNy9jaXRpZ3JvdXAtaW5jLXB1cmNoYXNlcy1uZXctcG9zaXRpb24taW4tbWluZC1tZWRpY2luZS1taW5kbWVkLWluYy1uYXNkYXFtbm1kLmh0bWzSAQA?oc=5","is_publish_highlight":false,"gpt_icon":0},{"id":"2420040224","title":"Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2420040224","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2420040224?lang=en_us&edition=fundamental","pubTime":"2024-03-18 23:23","pubTimestamp":1710775380,"startTime":"0","endTime":"0","summary":"Cybin Inc.’s CYBN shares were up 7.2% on Mar 15 after the company initiated a phase II proof-of-concept study evaluating its proprietary deuterated dimethyltryptamine molecule, CYB004, for the treatment of patients with generalized anxiety disorder .Per the company, the double-blind phase II CYB004-002 study will investigate the safety and efficacy of CYB004 in the given patient population. Patients will be divided into two groups. The first group of patients will receive two IM doses of CYB004, while the second group will take two low-dose control administrations of CYB004.The primary endpoint of the study is to see the change in the Hamilton Anxiety Rating Scale score from baseline at six weeks of treatment after the administration of the second dose.Meanwhile, the Montgomery-Asberg Depression Rating scale depression assessment, safety assessments, psychedelic experience assessment and the quality of life assessment remain the other endpoints of the above study.Top-line data from the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-cybn-begins-phase-ii-152300916.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419601820","title":"MNMD, SMR and VERI are among pre market gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2419601820","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2419601820?lang=en_us&edition=fundamental","pubTime":"2024-03-14 20:07","pubTimestamp":1710418039,"startTime":"0","endTime":"0","summary":"Gainers: CCSC Technology International  +33%. Turtle Beach  +26% Q4 earnings call release  Lithium Americas  +20% gains after report of expected $2B government loan.  SoundHound  +16%. ShiftPixy  +15%. BigBear.ai Holdings  +14%. Zoomcar Holdings  +13%. Spero Therapeutics  +13% Q4 earnings call release  Robinhood Markets  +12% says trading volumes rose across all asset classes in February.  Auddia  +11%. NuScale Power Corporation  +9%. Mind Medicine  +8%. Weibo Corp  +8% Q4 earnings call release  Gaxos  +7%. Unicycive Therapeutics  +10% rises 4% on $50M private placement.  Semilux International  +7%. Immuneering  +3% Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors.  Veritone  +6%. Bullfrog AI Holdings  +6%. Naas Technology  +6%. Dollar General  +6%. UiPath  +5% Q4 earnings call release    More on pre market gainers and stock  Veritone, Inc.  Q4 2023 Earnings Call Transcript Mind Medicine  Inc.  Q4 2023 Earn","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4079409-mnmd-smr-and-veri-are-among-pre-market-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2418301243","title":"MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2418301243","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2418301243?lang=en_us&edition=fundamental","pubTime":"2024-03-11 19:00","pubTimestamp":1710154800,"startTime":"0","endTime":"0","summary":"NEW YORK, March 11, 2024----Mind Medicine  Inc.   , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024.MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.MindMed trades on NASDAQ under the symbol MNMD and on the Cboe Canada  under the symbol MMED.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sEgLYNG7DMC_rvlcomR4VA--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c4ea94bd95ed8fa30cc7c035a9d09f6e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sEgLYNG7DMC_rvlcomR4VA--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c4ea94bd95ed8fa30cc7c035a9d09f6e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-participate-leerink-partners-2024-110000929.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2418781603","title":"Weekly Roundup on the Cannabis Sector & Psychedelic Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2418781603","media":"Market Exclusive","top":-1,"share":"https://ttm.financial/m/news/2418781603?lang=en_us&edition=fundamental","pubTime":"2024-03-10 23:10","pubTimestamp":1710083407,"startTime":"0","endTime":"0","summary":"Curaleaf reported strong growth in 2023, amidst global expansion plans.MariMed reported revenue growth and net loss in 2023; alongside 2024 growth forecast.Cronos Group reported improved financial performance in 2023.Planet 13 announced a public offering to raise $11.3 million.Awakn announced listing on the Canadian Securities Exchange.In this weekly roundup, we delve into the latest developments and initiatives across the cannabis and psychedelic sectors. From groundbreaking medical research to emerging therapeutic applications and shifts in legal frameworks.Looking ahead, Curaleaf stated that it is focused on expanding its footprint in both domestic and international markets. The company aims to capitalize on new opportunities in states such as New York, Ohio, Florida, and Pennsylvania, as well as key European countries like Germany, the U.K., and Poland. It also plans to leverage the recent legalization of cannabis in Germany to further its European presence.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-151007538.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2418077569","title":"Analyst Optimistic about Mind Medicine's MM120 and Raises Price Target by 46.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2418077569","media":"WallStreetZen","top":-1,"share":"https://ttm.financial/m/news/2418077569?lang=en_us&edition=fundamental","pubTime":"2024-03-09 19:58","pubTimestamp":1709985480,"startTime":"0","endTime":"0","summary":"RBC Capital's Brian Abrahams raised their price target on Mind Medicine (NASDAQ: MNMD) by 46.7% from $15 to $22 on 2024/03/08. The analyst maintained their Buy rating on the stock.Abraham expressed op","market":"us","thumbnail":"https://images.unsplash.com/photo-1613312328068-c9b6b76c9e8a?crop=entropy&cs=tinysrgb&fit=crop&fm=jpg&ixid=M3w0NDY2OTN8MHwxfGFsbHx8fHx8fHx8fDE3MDk4ODU0MjB8&ixlib=rb-4.0.3&q=80&w=260&utm_source=wallstreetzen&utm_medium=referral&utm_campaign=api-credit&h=180","type":0,"news_type":0,"thumbnails":["https://images.unsplash.com/photo-1613312328068-c9b6b76c9e8a?crop=entropy&cs=tinysrgb&fit=crop&fm=jpg&ixid=M3w0NDY2OTN8MHwxfGFsbHx8fHx8fHx8fDE3MDk4ODU0MjB8&ixlib=rb-4.0.3&q=80&w=260&utm_source=wallstreetzen&utm_medium=referral&utm_campaign=api-credit&h=180"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.wallstreetzen.com/news/analyst-optimistic-about-mind-medicine-s-mm120-and-raises-price-target-by-46-7","is_publish_highlight":false,"gpt_icon":0},{"id":"2418062173","title":"MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2418062173","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2418062173?lang=en_us&edition=fundamental","pubTime":"2024-03-08 23:46","pubTimestamp":1709912760,"startTime":"0","endTime":"0","summary":"Mind Medicine  Inc. MNMD announced that the FDA granted a breakthrough therapy designation to its lead candidate, MM120  for treating generalized anxiety disorder .The FDA grants breakthrough therapy designation to expedite the development and review of therapies for severe or life-threatening diseases where preliminary clinical evidence shows that therapy may provide substantial improvements over available treatments.Simultaneously, the company announced that the phase IIb MMED008 study, which evaluated a single oral dose of MM120  in GAD, met its key secondary endpoint by demonstrating clinically and statistically significant durability of activity seen through week 12 of treatment.MNMD stock surged 51.5% on Mar 7 following the announcement of the news.MindMed previously announced that treatment with a single dose of MM120 demonstrated rapid, clinically meaningful, and statistically significant improvements on the Hamilton Anxiety rating scale  versus placebo at week four of treatmen","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmeds-mnmd-anxiety-drug-gets-154600490.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mindmed.co","stockEarnings":[{"period":"1week","weight":0.1737},{"period":"1month","weight":-0.1489},{"period":"3month","weight":1.457},{"period":"6month","weight":2.2362},{"period":"1year","weight":1.7624},{"period":"ytd","weight":1.7322}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.138746},{"month":2,"riseRate":1,"avgChangeRate":0.220255},{"month":3,"riseRate":0.333333,"avgChangeRate":0.135594},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.020489},{"month":5,"riseRate":0.5,"avgChangeRate":-0.00561},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.089764},{"month":7,"riseRate":0.666667,"avgChangeRate":0.117736},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.029688},{"month":9,"riseRate":0,"avgChangeRate":-0.380307},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.087807},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.018305},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.110398}],"exchange":"NASDAQ","name":"Mind Medicine (MindMed) Inc.","nameEN":"Mind Medicine (MindMed) Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mind Medicine (MindMed) Inc.,MNMD,Mind Medicine (MindMed) Inc.股票,Mind Medicine (MindMed) Inc.股票老虎,Mind Medicine (MindMed) Inc.股票老虎国际,Mind Medicine (MindMed) Inc.行情,Mind Medicine (MindMed) Inc.股票行情,Mind Medicine (MindMed) Inc.股价,Mind Medicine (MindMed) Inc.股市,Mind Medicine (MindMed) Inc.股票价格,Mind Medicine (MindMed) Inc.股票交易,Mind Medicine (MindMed) Inc.股票购买,Mind Medicine (MindMed) Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}